Ebene Magazine – Biocon tanks 10% on lower-than-expected December quarter results en

Ebene Magazine - Biocon tanks 10% on lower-than-expected December quarter results en

SI Reporter  | 
Last Updated at January 22, 2021 10:26 IST

Shares of Biocon plunged 10 per cent to Rs 400 on the BSE in the morning deals on Friday after the company posted below par December quarter (Q3FY21) results, with consolidated net profit down 17 per cent year on year (YoY) at Rs 169 crore.

Ebitda (earnings before interest, taxes, depreciation, and amortization) declined 10.1 per cent YoY to Rs 400 crore, while Ebitda margins contracted 383 basis points YoY to 21.6 per cent mainly due to higher employee, R&D and other expenditure.document.write(« « );googletag.cmd.push(function(){googletag.defineOutOfPageSlot(‘/6516239/outofpage_1x1_desktop’,’div-gpt-ad-1490771277198-0′).addService(googletag.pubads());googletag.pubads().enableSyncRendering();googletag.enableServices();});

The company’s Q3FY21 revenue grew 5.9 per cent YoY to Rs 1,851 crore, led by biosimilars and research services segments. The growth was dragged down by generics sales – down 3 per cent YoY to Rs 561 crore.

The management said the generics business experienced a subdued performance in Q3 as demand moderated following a period of advance buying by customers in the first half of this fiscal, apprehending supply disruption in the wake of the pandemic. Growth, it said, was also impacted by delays in regulatory approvals of certain products that required physical inspection of the company’s facilities, due to Covid-19 related travel restrictions.

« The biosimilars segment revenue growth this quarter was driven by steady market share of the company’s products in the US and growth in key most of the world (MoW) markets including Africa, Middle East, Turkey (AFMET) and India, » the management said.

Meanwhile, due to « professional differences with the chairperson on strategic priorities and the vision for the company », Dr Christiane Hamacher has stepped down as the Managing Director (MD) of Biocon Biologics, a subsidiary of Biocon. She also ceased to be a member of the Board of Directors of Biocon Biologics effective from January 20, 2021.

« This decision was taken due to professional differences with the chairperson on strategic priorities and vision for the company. Her last working day as CEO would be February 28, 2021,” the company said in a statement.

Dr Arun Chandavarkar, Member of the Board of Biocon Biologics, took over as the new MD of Biocon Biologics effective Jan 21, 2021 for a period of up to two years.

At 10:05 am, Biocon was trading 9 per cent lower at Rs 402 on the BSE, as compared to a 0.11 per cent decline in the S&P BSE Sensex. Trading volumes on the counter more-than-doubled with a combined 11.6 million equity shares having changed hands on the NSE and BSE till the time of writing of this report.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is happy to inform you of the launch of « Business Standard Premium Services »

As a premium subscriber you get an across device unfettered access to a range of services which include:

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.
Enjoy Reading!
Team Business Standard

Related title:
Biocon tanks 10% on lower-than-expected December quarter results
Biocon Biologics reports topline of ₹769 crore in Q3
Why Biocon's Stock Tumbled Most In 10 Months
Biocon share price falls 9% after Q3 profit dips 18% YoY to Rs 186 crore
Biocon reports 17 pc dip in Q3 net profit at Rs 169 cr
Latest News | Biocon Q3 Net Profit Falls 19 Pc to Rs 186.6 Cr
Biocon slumps after Q3 PAT drops 17% YoY


Ref: https://www.business-standard.com



Laisser un commentaire, votre avis compte!

[gs-fb-comments] [comment-form]